BVF I GP LLC's Net Worth

$159 Million

Who is BVF I GP LLC?

BVF I GP LLC has an estimated net worth of $159 Million. This is based on reported shares across multiple companies, which include Allakos Inc., Rain Oncology Inc., XOMA Corp, Cullinan Oncology, Inc., Merus N.V., Repare Therapeutics Inc., Verastem, Inc., CTI BIOPHARMA CORP, IDEAYA Biosciences, Inc., CYTOKINETICS INC, Kymera Therapeutics, Inc., CytomX Therapeutics, Inc., MoonLake Immunotherapeutics, Principia Biopharma Inc., Eledon Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc., ESSA Pharma Inc., 4D Molecular Therapeutics, Inc., PIERIS PHARMACEUTICALS, INC., Third Harmonic Bio, Inc., FIVE PRIME THERAPEUTICS, INC., Structure Therapeutics Inc., enGene Holdings Inc., POINT Biopharma Global Inc., GLYCOMIMETICS INC, and INFINITY PHARMACEUTICALS, INC..

SEC CIK

BVF I GP LLC's CIK is 0001803805

Past Insider Trading and Trends

2020 was BVF I GP LLC's most active year for acquiring shares with 116 total transactions. BVF I GP LLC's most active month to acquire stocks was the month of April. 2020 was BVF I GP LLC's most active year for disposing of shares, totalling 33 transactions. BVF I GP LLC's most active month to dispose stocks was the month of May. 2021 saw BVF I GP LLC paying a total of $132,144,944.64 for 12,405,370 shares, this is the most they've acquired in one year. In 2020 BVF I GP LLC cashed out on 15,626,103.772 shares for a total of $157,004,308.58, their largest year based on trade value.